Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis
- 1Department of Experimental Hematology KU Leuven Leuven Belgium
- 2Department of Hematology, Internal Medicine University Hospitals Leuven Leuven Belgium
- 3Laboratory of Genetics of Malignant Disorders KU Leuven Leuven Belgium
Abstract
Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome (HES). Among the many causes of HE, rare hematological malignancies, in particular the “myeloid/lymphoid neoplasms (MLN) with eosinophilia and tyrosine kinase (TK) gene fusions,” represent phenotypically and prognostically heterogeneous and challenging entities. For this reason, the evaluation of HE constitutes a diagnostic and therapeutic challenge. In this review, we provide a concise overview of eosinophil biology, highlight their physiological role as regulators of immunity, tissue homeostasis, and inflammation, their involvement in diseases affecting nearly all organ systems, and in hematological malignancies in particular. Furthermore, we present a practical, stepwise diagnostic approach to HE, emphasizing early recognition of eosinophil‐mediated organ dysfunction to initiate timely treatment, as well as red flags that should raise further hematologic evaluation, including molecular and cytogenetic investigations to identify an underlying clonal disorder. Treatment strategies depend on the underlying etiology and range from supportive care, over corticosteroids to targeted biological therapies and tyrosine kinase inhibitors (TKIs).
Related
- An elusive diagnosis: pericardial effusion and hypereosinophilia revealing seronegative eosinophilic granulomatosis with polyangitis: a case report
- Navigating Treatment Pathways in Diabetic Foot Infection: A Practical Retrospective Analysis of Healing Predictors and the WIfI System.
- Navigating HPV vaccination challenges in low-resource settings: Practical strategies for estimating the size of out-of-school girls
- Pediatric Headache: A Practical Approach to Clinical Diagnosis and Management
- Non-diabetic endocrine neuropathies: A practical approach to diagnosis and clinical evaluation
BibTeX
@article{wigerinck2026eosinophilia,
title = {{Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis}},
author = {Stijn Wigerinck and Peter Vandenberghe},
journal = {European Journal of Haematology},
year = {2026},
month = sep,
doi = {10.1111/ejh.70299},
url = {https://doi.org/10.1111/ejh.70299},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis
AU - Stijn Wigerinck
AU - Peter Vandenberghe
PY - 2026
DA - 2026/09/01
JO - European Journal of Haematology
DO - 10.1111/ejh.70299
UR - https://doi.org/10.1111/ejh.70299
AB - Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome (HES). Among the many causes of HE, rare hematological malignancies, in particular the “myeloid/lymphoid neoplasms (MLN) with eosinophilia and tyrosine kinase (TK) gene fusions,” represent phenotypically and prognostically heterogeneous and challenging entities. For this reason, the evaluation of HE constitutes a diagnostic and therapeutic challenge. In this review, we provide a concise overview of eosinophil biology, highlight their physiological role as regulators of immunity, tissue homeostasis, and inflammation, their involvement in diseases affecting nearly all organ systems, and in hematological malignancies in particular. Furthermore, we present a practical, stepwise diagnostic approach to HE, emphasizing early recognition of eosinophil‐mediated organ dysfunction to initiate timely treatment, as well as red flags that should raise further hematologic evaluation, including molecular and cytogenetic investigations to identify an underlying clonal disorder. Treatment strategies depend on the underlying etiology and range from supportive care, over corticosteroids to targeted biological therapies and tyrosine kinase inhibitors (TKIs).
SN - 0902-4441
SN - 1600-0609
ER -